lurbinectedin + osimertinib

Lurbinectedin + osimertinib is an investigational combination therapy comprising two small molecule drugs: lurbinectedin, a selective inhibitor of oncogenic transcription approved for metastatic small cell lung cancer (SCLC), and osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-mutated non-small cell lung cancer (NSCLC). This combination is being studied primarily in patients with EGFR-mutant NSCLC who develop resistance to EGFR TKIs via histological transformation to SCLC—a clinical scenario with limited treatment options. Preclinical models and early case series suggest that the combination can induce significant tumor regression in transformed SCLC, likely by targeting both the original EGFR-driven pathway and mechanisms relevant to SCLC biology[1][2][3].

Brand names

Zepzelca (lurbinectedin)Tagrisso (osimertinib)

Other names

lurbinectedin plus osimertinib